Reduced risk of secondary primary extra pulmonary cancer in advanced/metastatic lung cancer patients treated with immune checkpoint inhibitors

Pierre-Étienne Heudel; Anne Montfort; D. Debieuvre; C. Chouaïd; Matthieu Carton; Clarisse Audigier-Valette; Thomas Filleron; Sylvie Chabaud; A. Stancu; Xavier Quantin; Sandrine Hiret; L. Bosquet; Jean Yves Blay

doi:10.1016/j.lungcan.2023.107280

Related publications

Letter2020

Reduced risk of second primary cancer in patients treated with immune checkpoint inhibitors for a first cancer

Pierre-Étienne Heudel, Sylvie Chabaud, David Pérol, I. Ray-Coquard, Jean Yves Blay

Article2021

Nephrotoxicity in patients with cancer treated with immune checkpoint inhibitors.

Evangelos Eleutherakis Papaiakovou, Efstathios Kastritis, Flora Zagouri, Dimitra Grapsa, Ioannis Ntanassis-Stathopoulos, Dimitra Stefanou, George Evangelou, Ilias Kotteas, Meletios A Dimopoulos, Konstantinos Syrigos

Article2025

Impact of Immune Checkpoint Inhibitors on Second Primary Cancer Risk in Patients With Metastatic Lung Cancer Using Real-World Data From the TriNetX Network: Retrospective Cohort Study

Pierre-Étienne Heudel, Gema Hernandez, Olivier Denquin, Hugo Crochet, Jean Yves Blay

Article2017

Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

Tuba N. Gide, James S. Wilmott, Richard A Scolyer, Georgina V. Long

Article2023

Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors

Linda Y. Wu, Grace van Hyfte, Umut Özbek, Marlene Reincke, Anuhya Gampa, Yehia I. Mohamed, Naoshi Nishida, Brooke Wietharn, Suneetha Amara, Pei‐Chang Lee, Bernhard Scheiner, Lorenz Balcar, Matthias Pinter, Arndt Vogel, Arndt Weinmann, Anwaar Saeed, Anjana Pillai, Lorenza Rimassa, Abdul Rafeh Naqash, Mahvish Muzaffar, Yi‐Hsiang Huang, Ahmed O. Kaseb, Masatoshi Kudo, ,